VIVO - メリディアン・バイオサイエンス (Meridian Bioscience Inc.) メリディアン・バイオサイエンス

 VIVOのチャート


 VIVOの企業情報

symbol VIVO
会社名 Meridian Bioscience Inc. (メリディアン・バイオサイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 メリディアン・バイオサイエンス(Meridian Bioscience Inc.)は胃腸、呼吸器、ウイルス、寄生虫感染症、血液鉛濃度の上昇を対象とした診断検査キットの開発・製造・販売、研究者と他の診断メーカーが使用するバルク抗原、抗体、ポリメラーゼ連鎖反応(PCR)・定量PCR(qPCR)試薬、ヌクレオチド、コンピテントセルおよびバイオリサーチ試薬の製造・販売に従事するライフサイエンス会社である。同社のセグメントには、診断およびライフサイエンスが含まれる。診断セグメントにはシンシナティにおいて製造事業、北米、中南米、ヨーロッパ、中東およびアフリカ(EMEA)および米州およびEMEA外の他の国々などにおいて診断テストキットの販売と流通を行う。ライフサイエンス事業はテネシー州メンフィス、フロリダ州ボカラトン、イギリスロンドン、ドイツのルッケンヴァルデ、オーストラリアのシドニーにある製造事業を行う。   メリディアン・バイオサイエンスは、米国のライフサイエンス事業会社。おもに胃腸、ウイルス、呼吸器、寄生虫感染症などの診断検査キットの開発、製造、販売を行う。バルク抗原、抗体、PCR/qPCR試薬、ヌクレオチド、コンピテント細胞、バイオ研究用試薬の製造、販売のほか、新薬・ワクチン研究用に、タンパク質と生物学的製剤の受託開発・製造を手掛ける。   Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
本社所在地 3471 River Hills Drive Cincinnati OH 45244 USA
代表者氏名 David C. Phillips デビッド・C.フィリップス
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 513-271-3700
設立年月日 27912
市場名 NASDAQ National Market System
ipoyear 1986年
従業員数 640人
url www.meridianbioscience.com
nasdaq_url https://www.nasdaq.com/symbol/vivo
adr_tso
EBITDA EBITDA(百万ドル) 44.73600
終値(lastsale) 14.67
時価総額(marketcap) 621939373.74
時価総額 時価総額(百万ドル) 660.09520
売上高 売上高(百万ドル) 210.16800
企業価値(EV) 企業価値(EV)(百万ドル) 653.46220
当期純利益 当期純利益(百万ドル) 22.64800
決算概要 決算概要 BRIEF: For the nine months ended 30 June 2018 Meridian Bioscience Inc. revenues increased 6% to $160.5M. Net income before extraordinary items increased 7% to $16.9M. Revenues reflect US Diagnostics segment increase of 6% to $113.6M Life Sciences segment increase of 8% to $46.8M. Net income benefited from US Diagnostics segment income increase of 25% to $21.4M. Dividend per share decreased from $0.45 to $0.38.

 VIVOのテクニカル分析


 VIVOのニュース

   Vivo Y51A ,   2021/06/28 09:01:09 Maharashtra Times
Vivo Y51A , . Vivo India - , .
   Vivo Y51A 6GB ,   2021/06/28 08:46:58 NBT Hindi News
, 11, 5000 Vivo Y51A
   50 iPhone 11, Mi 10, OnePlus 9 5   2021/06/28 01:46:53 NBT Hindi News
50 Apple iPhone 11, Samsung Galaxy S20 FE 5G, OnePlus 9, Vivo X60 Pro Xiaomi Mi 10 5 , ,
   Vivo X60T Pro+ 50 MP 55W , X60 Pro+ ?  2021/06/28 00:43:43 NBT Hindi News
Vivo Vivo S60 Series Vivo X60T Pro+ , Vivo X60 Pro+
   5   2021/06/27 19:05:57 218TV
5 Vivo X60t Pro Plus. Snapdragon 888 Adreno 660 Android 11 Origin OS 1.0. AMOLED 6.56 FHD Plus 2376*1080 The post 5 appeared first on 218 .
   VIVO Cannabis™ Announces Closing of $8 Million Overnight Marketed Public Offering Including Full Exercise of Over-Allotment Option  2021/02/26 14:59:00 Cision (Canada)
/CNW/ - VIVO Cannabis Inc. (TSX: VIVO) ("VIVO" or the "Company") announced today the closing of its previously announced overnight marketed public offering…
   GI Stool Testing Market 2021 Leading Countries, Challenges, Five Forces Analysis, Trends, Drivers, Forecast to 2023 | BioMrieux Inc. Meridian Bioscience Inc. DiaSorin S.p.A. Beckman Coulter Inc. Alere Inc.  2021/02/24 14:07:51 OpenPR
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, ‘GI Stool Testing Market: Global Opportunity Analysis and Industry Forecast 2020-2027’. The GI Stool Testing Market is expected to witness growth in upcoming years due to factors such as increase in
   Cannabis Stock Gainers And Losers From February 11, 2021  2021/02/11 22:24:49 Benzinga
GAINERS: MGC Pharmaceuticals (PINK: MGCLF ) shares closed up 32.23% at $0.05 Pharmadrug (PINK: LMLLF ) shares closed up 5% $0.10 BioHarvest Sciences (PINK: CNVCF ) shares closed up 21.35% at$0.54 Abattis Bioceuticals (PINK: ATTBF ) shares closed up 17.65% at $0.04 Target Group (OTCQB: CBDY ) shares closed up 10.32% at $0.07 Meridian Bioscience (OTCQX: VIVO ) shares closed up 8.89% at $29.89 22nd Century Group, Inc. Common Stock (NYSEMKT: XXII ) shares closed up 7.16% at $3.74 Zelira Therapeutics (OTCQB: ZLDAF ) shares closed up 6.31% at $0.08 Teradyne (OTC: TER ) shares closed up 4.92% at $135.04 AusCann Group Holdings (PINK: ACNNF ) shares closed up 3.23% at $0.16 World Acceptance ( WRLD ) shares closed up 2.35% at $128.88 Full story available on Benzinga.com
   Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day  2021/02/11 14:01:02 Yahoo Finance UK
Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day
   John P. Kenny Sells 68,288 Shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) Stock  2021/02/10 20:30:43 Watchlist News
Meridian Bioscience, Inc. (NASDAQ:VIVO) CEO John P. Kenny sold 68,288 shares of the stock in a transaction dated Monday, February 8th. The stock was sold at an average price of $29.86, for a total value of $2,039,079.68. Following the completion of the sale, the chief executive officer now directly owns 304,330 shares of the company’s […]
   Meridian Bioscience, Inc. to Host Earnings Call  2021/02/05 13:15:00 Yahoo Finance
NEW YORK, NY / ACCESSWIRE / February 5, 2021 / Meridian Bioscience, Inc. (NASDAQ:VIVO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on February 5, 2021 at 10:00 AM Eastern Time.
   H.C. Wainwright Stick to Their Buy Rating for Meridian Bioscience Inc. By Investing.com  2021/02/04 11:29:06 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Meridian Bioscience Inc.
   Meridian’s Air-Dryable Master Mixes Replace Lyophilization in the Manufacturing of Molecular Assays  2021/02/02 13:00:00 Yahoo Finance
CINCINNATI, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has developed a series of innovative and high performing master mixes designed for manufacturing room-temperature stable molecular diagnostic assays that do not require lyophilization. The conventional approach to manufacture room-temperature stable molecular assay is lyophilization, which is expensive, time consuming, and requires expertise and sophisticated equipment. Meridian’s new air-dryable master mixes for DNA/RNA detection replace the need for lyophilization with a fast, simple and inexpensive oven-drying procedure. A unique advantage of Meridian’s air-dryable master mixes is their ability to effectively preserve the performance and integrity of the enzymes throughout the oven-drying process. Meridian’s air-dryable master mixes also exhibit higher tolerance to PCR inhibitors, when compared to lyophilized or liquid-formats, regardless of the sample type (e.g., urine, stool, blood, saliva, waste water, plant, etc.) In addition, air-dryable master mixes are ideal for molecular assays that require multiplexing or are price sensitive.
   FXNEWS24 |Meridian Bioscience (VIVO) Gains As Market Dips: What You Should Know | UK Forex Reviews  2021/01/30 04:01:23 FXNews24
Meridian Bioscience (VIVO) Gains As Market Dips: What You Should Know | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Global Preliminary Screening Tests Market 2021:Thriving Worldwide||Players-Bio-rad Laboratories, Inc., Cepheid., Hologic Inc., Meridian Bioscience, Inc., OraSure Technologies  2021/01/25 13:13:59 OpenPR
The demand for preliminary screening tests is projected to achieve market share over the 2020 to 2027 forecast period. Data Bridge Market Research analyses the demand in the projected timeframe to expand at a CAGR of 7.11 percent. Increasing awareness

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 メリディアン・バイオサイエンス VIVO Meridian Bioscience Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)